AV
AverageSven
Community Contributor
Member since 2025
Views8Total number of views
Followers0Total number of followers
Comments0Total number of comments
No bio added yet
No link added
TERN: Positioned for Dominance – The Intrinsic Value of TERN-701 Points to $98.57
TERN: Positioned for Dominance – The Intrinsic Value of TERN-701 Points to $98.57 Terns Pharmaceuticals (TERN) is fundamentally undervalued based on the clinical profile of its lead oncology asset, TERN-701. The latest data establish a clear trajectory for market leadership in Chronic Myeloid Leukemia (CML), justifying an intrinsic valuation target of 98.57 per share.Read more
8
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AV
US$98.57
62.3% undervalued intrinsic discount
AverageSven's Fair Value
Profit Margin
15.39%
Future PE
22.83x
Price in 2030
US$0